Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE:BMY) has received a positive opinion from the CHMP for the combination therapy of Opdivo (nivolumab) and chemotherapy for first-line treatment of adults with unresectable advanced esophageal squamous cell carcinoma (ESCC) with PD-L1 expression ≥1%. This recommendation is based on the Phase 3 CheckMate -648 trial, which showed a significant overall survival benefit (median 15.4 months vs. 9.1 months) for the combination versus chemotherapy alone. The European Commission will review this opinion next.
Bristol Myers Squibb (NYSE:BMY) announced a positive CHMP opinion recommending approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for first-line treatment of unresectable advanced esophageal squamous cell carcinoma (ESCC) with PD-L1 expression ≥1%. This follows promising results from the Phase 3 CheckMate -648 trial, where the combination therapy showed a median overall survival of 13.7 months compared to 9.1 months for chemotherapy (HR = 0.64; p=0.001). The European Commission will now review this recommendation.
Biohaven Pharmaceutical announced a worldwide licensing agreement with Bristol Myers Squibb for the development of taldefgrobep alfa, a Phase 3-ready anti-myostatin adnectin targeted at treating Spinal Muscular Atrophy (SMA). This is Biohaven's third license from Bristol Myers Squibb, with the trial expected to commence in 2022. Taldefgrobep aims to enhance muscle mass and strength in patients with neuromuscular diseases, representing a potential breakthrough in treatment strategies. The agreement includes milestone payments and sales-based royalties for Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) has received a positive recommendation from the European Medicines Agency's CHMP for the approval of Opdivo (nivolumab) for adjuvant treatment of adults with muscle-invasive urothelial carcinoma at high risk of recurrence post-surgery.
This recommendation is based on the Phase 3 CheckMate -274 trial results, which showed significant disease-free survival improvement with Opdivo versus placebo. If approved, it would be the first adjuvant immunotherapy option in Europe for this patient group.
Bristol Myers Squibb (NYSE: BMY) announced positive interim results from the True North study, revealing sustained efficacy of Zeposia (ozanimod) in treating moderately to severely active ulcerative colitis through Week 142. Key findings include that 45% to 51% of patients achieved clinical remission at Weeks 46, 94, and 142, while clinical response rates ranged from 80% to 86%. No new safety signals emerged, reinforcing Zeposia as a significant treatment option in this patient group. The data will be presented at the ECCO 2022 Congress.
Bristol Myers Squibb announced that the FDA has accepted its supplemental Biologics License Application for Breyanzi, a CAR T cell therapy, seeking to expand its use for adults with relapsed or refractory large B-cell lymphoma after first-line therapy failure. The application received Priority Review status, with a target action date of June 24, 2022.
Results from the pivotal Phase 3 TRANSFORM study indicated Breyanzi provided significant improvements in event-free survival and overall outcomes compared to standard chemotherapy treatments.
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 VALOR-HCM trial evaluating mavacamten for symptomatic obstructive hypertrophic cardiomyopathy met its primary endpoint at Week 16. The trial involved over 100 patients and showed consistent safety results with previous studies. Mavacamten aims to improve patient outcomes eligible for septal reduction therapy. The firm plans to submit these findings to regulatory authorities and will present more data at the American College of Cardiology's Annual Scientific Session in April.
Bristol-Myers Squibb Company (NYSE:BMY) has priced a public offering of senior unsecured notes totaling $6 billion. The notes are issued in four tranches with varying interest rates and maturity dates: $1.75 billion at 2.950% due 2032, $1.25 billion at 3.550% due 2042, $2 billion at 3.700% due 2052, and $1 billion at 3.900% due 2062. The offering is expected to close on March 2, 2022. Proceeds will fund a concurrent tender offer, repay outstanding debt, and cover general corporate expenses.
Bristol-Myers Squibb (NYSE:BMY) and its subsidiary Celgene Corporation announced the launch of offers to purchase up to $4 billion in notes. The Offers involve 22 separate series of Notes from 2025 to 2097, with aggregate purchase prices ranging from $500 million to $1.25 billion for each pool. The Offers aim to acquire maximum principal amounts based on priority levels, subject to financing conditions. Early tender premiums of $50 are also included. The Offers will expire on March 15, 2022, with prior deadlines for total consideration eligibility.
Bristol Myers Squibb (BMY) and Exelixis (EXEL) report updated results from the CheckMate -9ER trial at ASCO GU 2022, highlighting the superiority of the Opdivo (nivolumab) and Cabometyx (cabozantinib) combination over sunitinib for advanced renal cell carcinoma. With a median follow-up of 32.9 months, patients receiving the combination achieved a median overall survival of 37.7 months and a progression-free survival of 16.6 months. No new safety concerns were identified, and health-related quality of life was significantly improved in the combination group.